MedTrace Logo

Phase 2 Study of KH001 in Long-term Relief From Dentin Hypersensitivity

NCT06464939 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-01-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of KH001 in subjects with dentin hypersensitivity.

Conditions

  • Dentin Hypersensitivity

Interventions

DRUG

KH001

Applications of KH001 over a 1 or 2-week period, and application of placebo

DRUG

Placebo

Applications of water for injection

Sponsors & Collaborators

  • The Forsyth Institute

    collaborator OTHER

  • HysensBio Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Hatice Hasturk · ADA Forsyth

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-08
Primary Completion
2025-12-22
Completion
2025-12-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06464939 on ClinicalTrials.gov